<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02272478</url>
  </required_header>
  <id_info>
    <org_study_id>AML18</org_study_id>
    <nct_id>NCT02272478</nct_id>
  </id_info>
  <brief_title>Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations</brief_title>
  <acronym>AML18</acronym>
  <official_title>A Trial for Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiff University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cardiff University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The AML18 Trial will evaluate several relevant therapeutic questions in Acute Myeloid&#xD;
      Leukaemia (AML), as defined by the WHO, and High Risk Myelodysplastic Syndrome. The trial is&#xD;
      primarily designed for patients over 60 years considered fit for an intensive&#xD;
      chemotherapeutic approach, but younger patients who may not be considered suitable for the&#xD;
      concurrent NCRI AML Trial for younger patients may also enter. Patients for whom intensive&#xD;
      chemotherapy is not thought suitable may enter the concurrent NCRI trial of less intensive&#xD;
      therapy (LI1). Approximately 1600 patients will be recruited.&#xD;
&#xD;
      At entry, a randomisation will compare a standard chemotherapy schedule DA&#xD;
      (Daunorubicin/Ara-C) combined with 1 dose of Mylotarg (gemtuzumab ozogamicin, or GO) in&#xD;
      course 1 against CPX-351. Patients who have known adverse risk cytogenetics (using Grimwade&#xD;
      2010 classification favourable/intermediate/adverse) at diagnosis may enter a Phase 2&#xD;
      evaluation of the combination of Vosaroxin plus Decitabine. Patients who achieve complete&#xD;
      remission (CR) and who are MRD negative by flow cytometry after course one of DA will receive&#xD;
      one further course of DA, with a randomisation to receive, either a course of DA or&#xD;
      intermediate dose Cytarabine (IDAC) as a third course. Patients who are MRD negative by flow&#xD;
      cytometry after course one of CPX-351 will receive up to 2 further course of CPX. Patients&#xD;
      who fail to achieve a CR after course 1 of DA or who are MRD positive by flow cytometry or&#xD;
      for whom MRD information is not available, are eligible to be randomised to compare DA with&#xD;
      DA plus Cladribine (DAC) or FLAG-Ida for up to two courses of therapy. Patients who fail to&#xD;
      achieve a CR after course 1 of CPX-351 or who are MRD positive by flow cytometry or for whom&#xD;
      MRD information is not available are eligible to be randomised between a second course of&#xD;
      standard dose CPX versus a repeat of the course 1 schedule. Patients receiving Vosaroxin and&#xD;
      Decitabine are excluded from these post course 1 randomisations .&#xD;
&#xD;
      Following the outcome of course 1, patients who received DA chemotherapy on course 1 will be&#xD;
      randomised to receive further chemotherapy with the 2nd generation FLT3 inhibitor AC220.&#xD;
      Patients randomised to AC220 will be allocated a maximum of 3 courses (short AC220) or 3&#xD;
      courses plus maintenance for 1 year (long AC220). Patients receiving Vosaroxin and Decitabine&#xD;
      are excluded from this randomisation.&#xD;
&#xD;
      Patients will be eligible for a non-intensive allogeneic stem cell transplant if a suitable&#xD;
      HLA matched donor is available.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AML18 is a trial primarily for older patients with AML and high risk Myelodysplastic Syndrome&#xD;
      (MDS). It offers a randomised controlled Phase II/III trial which uses a factorial design for&#xD;
      maximum efficiency to evaluate two induction options followed by treatment with small&#xD;
      molecule beyond course 1, and dose intensification for patients without evidence of MRD&#xD;
      negativity.&#xD;
&#xD;
      There are five randomised comparisons within the trial:&#xD;
&#xD;
        1. At diagnosis:&#xD;
&#xD;
           For patients not known to have adverse risk cytogenetics DA chemotherapy plus a single&#xD;
           dose of 3 mg/m2 of Mylotarg versus CPX-351. Patients with abnormal LFTs can enter the&#xD;
           randomisation but receive DA alone or CPX-351.&#xD;
&#xD;
        2. For patients who received DA chemotherapy but are not in CR or who are MRD +ve, or for&#xD;
           whom MRD is not assessable.&#xD;
&#xD;
           DA versus DAC versus FLAG-Ida&#xD;
&#xD;
        3. All patients at second course who have received DA and have not received Vosaroxin and&#xD;
           Decitabine induction AC220 versus no AC220 for a maximum of 3 cycles; then with or&#xD;
           without maintenance for 1 year for patients allocated AC220&#xD;
&#xD;
        4. For patients who are in CR or CRi and MRD -ve post course1 and have completed 2 courses&#xD;
           of DA DA versus intermediate dose Cytarabine (IDAC)&#xD;
&#xD;
        5. For patients who received CPX-351 chemotherapy but are not in CR or who are MRD +ve, or&#xD;
           for whom MRD is not assessable CPX-351 100 units/m2 x 3 doses versus CPX-351 100&#xD;
           units/m2 x 2 doses&#xD;
&#xD;
      The trial will also assess:&#xD;
&#xD;
        -  Non-intensive allogeneic stem cell transplant for patients with matched sibling or&#xD;
           matched unrelated donors.&#xD;
&#xD;
        -  The combination of Vosaroxin and Decitabine for those with known adverse risk&#xD;
           cytogenetics at diagnosis&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 30, 2014</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete remission (CR + CRi) achievement and reasons for failure (for induction questions)</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of remission, relapse rates and deaths in first CR</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity, both haematological and non-haematological</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Supportive care requirements (and other aspects of health economics)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The relevance of the presence of a cytogenetic abnormality in the bone marrow of patients in morphological remission</measure>
    <time_frame>At study end</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The relevance of molecular characteristics and response to treatment</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To store diagnostic tissue for future research in the AML Tissue Bank</measure>
    <time_frame>6 years</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">1600</enrollment>
  <condition>Acute Myeloid Leukaemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients not known adverse karyotype&#xD;
Randomise between&#xD;
Daunorubicin 60mg/m2 daily by i.v. infusion on days 1, 3 and 5 (3 doses) Cytosine Arabinoside 100mg/m2 12 hourly by i.v. push on days 1 - 10 inclusive (20 doses) Mylotarg (GO) 3mg/m2 on day 1 of DA chemotherapy&#xD;
Versus&#xD;
CPX-351 100 units/m2 on days 1, 3 and 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with known adverse karyotype&#xD;
5 cycles of Vosaroxin and Decitabine therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prior to Course 2 - Patients receving DA plus GO in course 1 and MRD positive PC1&#xD;
Randomise between&#xD;
Daunorubicin 50mg/2 daily by i.v. infusion on days 1, 3 and 5 (3 doses) Cytosine Arabinoside 100mg/m2 12 hourly by i.v.push on days 1 - 8 inclusive (16 doses)&#xD;
Versus&#xD;
Daunorubicin 50mg/m2 daily by i.v. infusion on days 1, 3 and 5 Cytosine Arabinoside 100mg/m2 12 hourly by i.v. push on days 1 - 8 inclusive Cladribine 5mg/m2 daily on days 1 - 5 inclusive&#xD;
Versus Patients aged 60-69 Fludarabine 30mg/m2 daily on i.v. on days 2 - 6 inclusive Cytosine Arabinoside 1g/m2 daily over 4 hours Fludarabine on days 2 - 6 inclusive&#xD;
Patients aged 70+ Fludarabine 25mg/m2 daily i.v. on days 2 - 5 inclusive Cytosine Arabinoside 1g/m2 daily over 4 hours Fludarabine on days 2 - 5 inclusive Idarubicin 5mg/m2 i.v. daily on days 3, 4 and 5 (3 doses)&#xD;
And Randomisation to receive AC220 or not</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prior to Course 2 - Patients that received DA plus GO in course 1 and MRD negative PC1&#xD;
Randomisation to receive AC220 or not</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm E</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prior to Course 2 for patients receiving CPX in course 1 and MRD positive PC1&#xD;
Randomisation between&#xD;
CPX-351 100 units/m2 on days 1, and 3 (CPX 200) versus CPX-351 100 units/m2 on days 1, 3 and 5 (CPX 300)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm F</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prior to Course 3 - Patients that received DA plus GO in course 1 and MRD negative PC1&#xD;
Randomise between Daunorubicin 50 mg/m2 daily by i.v. infusion on days 1 and 3 (2 doses) Cytosine Arabinoside 100 mg/m2 12-hourly by i.v. push on days 1 - 5 inclusive (10 doses)&#xD;
versus&#xD;
Intermediate dose Cytarabine (IDAC) schedule Cytosine Arabinoside 1g/m2 daily by 4 hour infusion on days 1- 5 inclusive (5 doses)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm A Mylotarg plus DA Versus CPX-351</intervention_name>
    <description>Patients not known to have adverse risk cytogenetics will enter a randomisation comparing DA with Mylotarg (GO) delivered at 3mg/m2 on day 1 of chemotherapy, with CPX-351 on days 1, 3 and 5.</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Mylotarg (GO)</other_name>
    <other_name>CPX-351</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm B Vosaroxin and Decitabine</intervention_name>
    <description>If a patient is known to have adverse risk Cytogenetics at diagnosis they will enter a registration to receive up to 5 courses of Vosaroxin and Decitabine.</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Vosaroxin</other_name>
    <other_name>Decitabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm D Small molecule or Not</intervention_name>
    <description>The randomisation to AC220 or not will take place immediately before course 2 of treatment for patients who have received DA induction +/- Mylotarg, irrespective of residual disease status. Patients allocated to receive AC220 will be randomised in a 1:1 fashion to AC220 or no small molecule with a 1:1 randomisation in patients drawing AC220 between short and long therapy.</description>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
    <other_name>No AC220</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm C DA V FLAG-Ida V DAC</intervention_name>
    <description>If a patient is not in CR or CRi after course 1 or is MRD +ve/unknown by flow cytometry they will be eligible to be randomised in a 1:1:1 fashion between DA, FLAG-Ida (or mini FLAG-Ida if 70 years or older) and DAC.</description>
    <arm_group_label>Arm C</arm_group_label>
    <other_name>DA</other_name>
    <other_name>FLAG-Ida</other_name>
    <other_name>DAC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm E CPX-351 (200 V 300)</intervention_name>
    <description>If a patient is not in CR or CRi after course 1 or is MRD +ve/unknown by flow cytometry they will be eligible to be randomised in a 1:1 fashion between CPX given on days 1, 3 and 5 (3 doses) and CPX given on days 1 and 3 (2 doses).</description>
    <arm_group_label>Arm E</arm_group_label>
    <other_name>CPX-351</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm F DA V IDAC</intervention_name>
    <description>Following recovery from course 2, patients in the MRD-ve arm will be randomised between a further 5-day cycle of DA or a cycle of intermediate dose cytarabine (IDAC) as the third chemotherapy course.</description>
    <arm_group_label>Arm F</arm_group_label>
    <other_name>IDAC</other_name>
    <other_name>DA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients are eligible for the AML18 trial if:&#xD;
&#xD;
          -  They have one of the forms of acute myeloid leukaemia, except Acute Promyelocytic&#xD;
             Leukaemia as defined by the WHO Classification (Appendix A) this can be any type of de&#xD;
             novo or secondary AML - or high risk Myelodysplastic Syndrome, defined as greater than&#xD;
             10% marrow blasts (RAEB-2). (NB patients with prior MDS (&gt;10% blasts, RAEB2) have&#xD;
             received azacitidine are not eligible for the trial, but patients with &lt;10% who have&#xD;
             failed a hypomethylating agent and developed AML may enter the trial).&#xD;
&#xD;
          -  Patients should normally be over the age of 60, but patients under this age are&#xD;
             eligible if they are not considered eligible for the MRC AML19 trial please contact&#xD;
             the trial team for further information.&#xD;
&#xD;
          -  Patients entering the Vosaroxin/Decitabine arm must be over the age of 60 and have&#xD;
             known adverse risk cytogenetics.&#xD;
&#xD;
          -  They have given written informed consent.&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 × ULN (upper limit of normal)&#xD;
&#xD;
          -  Sexually mature males must agree to use an adequate and medically accepted method of&#xD;
             contraception throughout the study if their sexual partners are women of child bearing&#xD;
             potential (WOCBP). Men should be advised to not father a child while receiving trial&#xD;
             treatment. Similarly women must agree to adequate contraceptive measures and avoid&#xD;
             becoming pregnant while on protocol treatment. In both males and females these&#xD;
             measures must be in place for at least 3 months following completion of Decitabine and&#xD;
             at least 6 months after the last administration of Cladribine. The time period&#xD;
             following treatment with Decitabine where it is safe to become pregnant is unknown. In&#xD;
             the event of pregnancy at any point during the trial, the IMPs should be immediately&#xD;
             stopped and the Trial Team should be contacted and pregnancy reporting procedures&#xD;
             followed.&#xD;
&#xD;
          -  ECOG Performance Status of 0-2&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
        Patients are not eligible for the AML18 trial if:&#xD;
&#xD;
          -  They have previously received cytotoxic chemotherapy for AML [Hydroxycarbamide, or&#xD;
             similar low-dose therapy, to control the white count prior to initiation of intensive&#xD;
             therapy, is not an exclusion]&#xD;
&#xD;
          -  They are in blast transformation of chronic myeloid leukaemia (CML)&#xD;
&#xD;
          -  They have a concurrent active malignancy excluding basal cell carcinoma&#xD;
&#xD;
          -  They are pregnant or lactating&#xD;
&#xD;
          -  They have Acute Promyelocytic Leukaemia&#xD;
&#xD;
          -  Known infection with human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Patients with prior cumulative anthracycline exposure (from prior treatment of a non&#xD;
             AML cancer) of greater than 300 mg/m2 daunorubicin (or equivalent).&#xD;
&#xD;
          -  History of myocardial infarction (MI), unstable angina, cerebrovascular accident, or&#xD;
             transient ischemic attack (CVA/TIA) within 3 months before entry&#xD;
&#xD;
        Specific exclusion criteria for the Mylotarg Arm&#xD;
&#xD;
          -  Pre-existing liver impairment with known cirrhosis&#xD;
&#xD;
          -  Total bilirubin &gt; 1.5 x the upper limit of normal (ULN)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) &gt; 2.5 x ULN&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) &gt; 2.5 x ULN&#xD;
&#xD;
        Specific exclusion criteria for the Vosaroxin/Decitabine Entry&#xD;
&#xD;
          -  Total bilirubin &gt; 1.5 x the upper limit of normal (ULN),&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) &gt; 2.5 x ULN&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) &gt; 2.5 x ULN&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) &lt; 40% by multiple gated acquisition (MUGA)&#xD;
             scan or echocardiogram (ECHO)]&#xD;
&#xD;
        Specific exclusion criteria for CPX-351 treatment&#xD;
&#xD;
          -  Hypersensitivity to cytarabine, daunorubicin or liposomal products&#xD;
&#xD;
          -  History of Wilson's disease or other copper-metabolism disorder&#xD;
&#xD;
        Specific exclusion criteria for Cladribine&#xD;
&#xD;
        • Patient's serum creatinine must be within the local ULN to enter the randomisation.&#xD;
        Patients for whom this is not the case can be randomised between the remaining options.&#xD;
&#xD;
        In addition patients are not eligible for the AC220 randomisation if they have:&#xD;
&#xD;
        Cardiovascular System Exclusion Criteria:&#xD;
&#xD;
        Known serious cardiac illness or medical conditions, including but not limited to:&#xD;
&#xD;
        I. Clinically unstable cardiac disease, including unstable atrial fibrillation, symptomatic&#xD;
        bradycardia, unstable congestive heart failure, active myocardial ischemia, or indwelling&#xD;
        temporary pacemaker II. Ventricular tachycardia or a supraventricular tachycardia that&#xD;
        requires treatment with a Class Ia antiarrhythmic drug (e.g., quinidine, procainamide,&#xD;
        disopyramide) or Class III antiarrhythmic drug (e.g., sotalol, amiodarone, dofetilide). Use&#xD;
        of other antiarrhythmic drugs is permitted.&#xD;
&#xD;
        III. Use of medications that have been linked to the occurrence of torsades de pointes (see&#xD;
        Appendix for the list of such medications) IV. Second- or third-degree atrioventricular&#xD;
        (AV) block unless treated with a permanent pacemaker V. Complete left bundle branch block&#xD;
        (LBBB) VI. History of long QT Syndrome or a family member with this condition VII. Serum&#xD;
        potassium, magnesium, and calcium levels not outside the laboratory's reference range VIII.&#xD;
        QTc &gt;450 ms (average of triplicate ECG recordings); a consistent method of QTc calculation&#xD;
        must be used for each patient's QTc measurements. QTcF (Fridericia's formula) is preferred.&#xD;
        Please see the trial website for QTcF calculator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nigel Russell, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nottingham University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sophie King</last_name>
    <phone>02922510527</phone>
    <email>aml18@cardiff.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Severinsen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans B Ommen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herlev and Gentofte Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Schöllkopf, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrik M Overgaard, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Duruta Weber, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Roskilde Hospital</name>
      <address>
        <city>Roskilde</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Møller</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominic Culligan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Monklands Hospital</name>
      <address>
        <city>Airdrie</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Murphy, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ysbyty Gwynedd Hospital</name>
      <address>
        <city>Bangor</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jim Seale, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal United Hospital Bath</name>
      <address>
        <city>Bath</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Knechtli, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Belfast City Hospital</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary McMullin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Birmingham Heartland Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manos Nikolousis, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Craddock, DPhil</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Blackpool Victoria Hospital</name>
      <address>
        <city>Blackpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Cahalin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ysbyty Glan Clwyd</name>
      <address>
        <city>Bodelwyddan</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Earnest Heartin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pilgrim Hospital</name>
      <address>
        <city>Boston</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Kallmeyer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth General Hospital</name>
      <address>
        <city>Bournemouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Chacko, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bradford Royal Infirmary</name>
      <address>
        <city>Bradford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sam Ackroyd, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bristol Haematology &amp; Oncology Centre</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Priyanka Mehta, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kiran Tawana, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UHW</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4XN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Steve Knapper</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steve Knapper, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cheltenham General Hospital</name>
      <address>
        <city>Cheltenham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Rye, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Countess of Chester Hospital</name>
      <address>
        <city>Chester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arvind Pillai, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Richard's Hospital</name>
      <address>
        <city>Chichester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Santosh Narat, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Coventry and Warwickshire</name>
      <address>
        <city>Coventry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Harris, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Derby Teaching Hospital</name>
      <address>
        <city>Derby</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Amott, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Russell Hall</name>
      <address>
        <city>Dudley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rupert Hipkins, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ninewells Hospital</name>
      <address>
        <city>Dundee</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sudhir Tauro, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Johnson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Devon &amp; Exeter Hospital</name>
      <address>
        <city>Exeter</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Coppell, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mhairi Copland, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hairmyres Hospital</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Murphy, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The New Victoria Hospital</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gail Loud, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gloucestershire Royal Hospital</name>
      <address>
        <city>Gloucester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Rye, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>Hamstead</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Panagiotis Kottaridis, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Raigmore Hospital</name>
      <address>
        <city>Inverness</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Duncan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ipswich Hospital</name>
      <address>
        <city>Ipswich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahesh Prahladan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Crosshouse &amp; Ayr Hospital</name>
      <address>
        <city>Irvine</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Gordon, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kettering General Hospital</name>
      <address>
        <city>Kettering</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Kwan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Victoria Hospital</name>
      <address>
        <city>Kirkcaldy</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Campbell, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Forth Valley Royal Hospital</name>
      <address>
        <city>Larbert</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hugh Edwards, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Jame's University Hospital</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Kelly, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Hodgson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lincoln County Hospital</name>
      <address>
        <city>Lincoln</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Kallmeyer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aintree University Hospital</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vikram Singh, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amit Patel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guy's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kavita Raj, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathew Smith, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St George's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Klammer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Taussig, M.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College London Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A Khwaja, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maidstone District General Hospital</name>
      <address>
        <city>Maidstone</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evangelia Dimitriadou, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eleni Tholouli, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mike Dennis, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The James Cook University Hospital</name>
      <address>
        <city>Middlesbrough</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ray Dang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Milton Keynes</name>
      <address>
        <city>Milton Keynes</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moez Dungarwalla, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gail Jones, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northampton General Hospital</name>
      <address>
        <city>Northampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Parker, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norfolk &amp; Norwich University</name>
      <address>
        <city>Norwich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Collins, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospital</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nigel Russell, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Oldham Hospital</name>
      <address>
        <city>Oldham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Osborne, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paresh Vyas, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Medd, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Alexandra Hospital</name>
      <address>
        <city>Portsmouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Corser, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Whiston Hospital &amp; St Helens</name>
      <address>
        <city>Prescot</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toby Nicholson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen's Hospital</name>
      <address>
        <city>Romford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Greaves, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Salford Royal Hospital</name>
      <address>
        <city>Salford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rowena Thomas-Dewing, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Salisbury District Hospital</name>
      <address>
        <city>Salisbury</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Cullis, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wexham Park Hospital</name>
      <address>
        <city>Slough</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Offer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Richardon, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stafford Hospital</name>
      <address>
        <city>Stafford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Revell, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Royal Stoke</name>
      <address>
        <city>Stoke-on-Trent</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Srivinas Pillai, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunderland Royal Hospital</name>
      <address>
        <city>Sunderland</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shikha Chattree, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Helier Hospital</name>
      <address>
        <city>Sutton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Stern, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Singleton Hospital</name>
      <address>
        <city>Swansea</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Unmesh Monite, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Torbay District General Hospital</name>
      <address>
        <city>Torquay</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Turner, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Cornwall Hospital</name>
      <address>
        <city>Truro</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryson Pottinger, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hillingdon Hospital</name>
      <address>
        <city>Uxbridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Kaczmarski, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pinderfields Hospital</name>
      <address>
        <city>Wakefield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Moreton, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sandwell Hospital</name>
      <address>
        <city>West Bromwich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farooq Wandroo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arrowe Park Hospital</name>
      <address>
        <city>Wirral</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ranjit Dasgupta, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wishaw General Hospital</name>
      <address>
        <city>Wishaw</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Murphy, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Cross Hospital</name>
      <address>
        <city>Wolverhampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Whitmill, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Worcestershire Royal Hospital</name>
      <address>
        <city>Worcester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas Pemberton, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Worthing Hospital</name>
      <address>
        <city>Worthing</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Santosh Narat, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>York Hospital</name>
      <address>
        <city>York</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Bond, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 10, 2014</study_first_submitted>
  <study_first_submitted_qc>October 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2014</study_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cardiff University</investigator_affiliation>
    <investigator_full_name>Prof Nigel Russell</investigator_full_name>
    <investigator_title>Prof</investigator_title>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>MDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Gemtuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

